Insider Selling: Global Blood Therapeutics Inc (NASDAQ:GBT) Insider Sells 2,765 Shares of Stock

Global Blood Therapeutics Inc (NASDAQ:GBT) insider Lesley Ann Calhoun sold 2,765 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $54.36, for a total value of $150,305.40. Following the transaction, the insider now directly owns 887 shares of the company’s stock, valued at approximately $48,217.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Global Blood Therapeutics stock traded down $0.27 during trading hours on Friday, hitting $54.04. The stock had a trading volume of 739,100 shares, compared to its average volume of 781,103. The company has a 50-day moving average of $49.97 and a two-hundred day moving average of $54.43. The company has a quick ratio of 16.79, a current ratio of 16.79 and a debt-to-equity ratio of 0.03. The company has a market cap of $3.25 billion, a PE ratio of -15.85 and a beta of 1.58. Global Blood Therapeutics Inc has a fifty-two week low of $30.15 and a fifty-two week high of $64.94.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.05). During the same quarter in the previous year, the business earned ($0.78) earnings per share. As a group, analysts forecast that Global Blood Therapeutics Inc will post -3.98 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. Luminus Management LLC acquired a new position in Global Blood Therapeutics in the 2nd quarter valued at approximately $20,368,000. Magnetar Financial LLC acquired a new position in shares of Global Blood Therapeutics in the 2nd quarter worth approximately $1,578,000. Perceptive Advisors LLC raised its holdings in shares of Global Blood Therapeutics by 4.5% in the 2nd quarter. Perceptive Advisors LLC now owns 5,775,726 shares of the company’s stock worth $303,803,000 after buying an additional 250,000 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. raised its holdings in shares of Global Blood Therapeutics by 6,110.0% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,968 shares of the company’s stock worth $261,000 after buying an additional 4,888 shares in the last quarter. Finally, United Services Automobile Association raised its holdings in shares of Global Blood Therapeutics by 1.3% in the 2nd quarter. United Services Automobile Association now owns 65,201 shares of the company’s stock worth $3,430,000 after buying an additional 863 shares in the last quarter. 97.99% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently weighed in on GBT shares. Cowen set a $83.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Thursday, September 5th. BidaskClub raised Global Blood Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 6th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Global Blood Therapeutics in a report on Thursday, September 5th. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $75.00 price target on shares of Global Blood Therapeutics in a report on Wednesday, May 29th. Finally, Wedbush reaffirmed a “buy” rating and issued a $120.00 price target on shares of Global Blood Therapeutics in a report on Thursday. One analyst has rated the stock with a sell rating, three have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $89.75.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Further Reading: What is a good rate of return for a mutual fund?

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.